Inhibikase Therapeutics, Inc. (IKT) intrinsic value & 10-year financials
Inhibikase Therapeutics, Inc. (IKT) has a Graham intrinsic value of $20.10 per share. At $1.65 on Oct 17, 2026, the stock trades 92% below that value.
- Graham intrinsic value
- $20.10
- Share price (Oct 17, 2026)
- $1.65
- Price vs Graham value
- 92% below
- Market cap
- $162.2M
- Revenue (FY2025)
- —
- Revenue growth (7-yr CAGR)
- -28.0%
- ROIC (10-yr avg)
- -204.6%
- Free cash flow (FY2025)
- -$27.8M
IKT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$48.3M | -$0.49 | -$27.8M | — | -38.8% |
| FY2024 | $0 | -$27.5M | -$0.29 | — | — | -1254.0% |
| FY2023 | $260.5K | -$19.0M | -$0.89 | -$18.1M | -7712.0% | -233.0% |
| FY2022 | $123.4K | -$18.1M | -$0.18 | -$17.6M | -14686.2% | -295.6% |
| FY2021 | $3.1M | -$14.8M | -$0.20 | — | -476.2% | 520.0% |
| FY2020 | $698.5K | -$2.8M | — | — | -403.5% | 74.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Inhibikase Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Inhibikase Therapeutics, Inc. returns on capital have been average, hovering around 12.3% ROIC over the decade.
Inhibikase Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Inhibikase Therapeutics, Inc. is modeled at -28.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $20.10 per share.